Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: Assessment of clinical consequences

Supportive Care in Cancer

Volumn 16, Issue 4, 2008, Pages 393-398

  Schwartzberg, Lee S ^a,c   Stepanski, Edward J ^a   Fortner, Barry V ^a,b,c   Houts, Arthur C ^b,c  

^a Accelerated Community Oncology Research Network   (United States)

^b Supportive Oncology Services   (United States)

^c WEST CLINIC   (United States)

Author keywords

Adverse events; Chemotherapy; Infusion reaction; Monoclonal antibody

Indexed keywords

ADRENALIN; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ATROPINE; BEVACIZUMAB; CETUXIMAB; CORTICOSTEROID; HISTAMINE H2 RECEPTOR ANTAGONIST; IRINOTECAN; LORAZEPAM; NARCOTIC AGENT; PARACETAMOL; RITUXIMAB; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG INFUSION REACTION; DRUG WITHDRAWAL; FEMALE; FLUID THERAPY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OXYGEN THERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 43449110961     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0329-5     Document Type: Article

References (11)

1. ASCO (1996) Status of the medical oncology workforce. The American Society of Clinical Oncology. J Clin Oncol 14(9):2612-2621
2. Genentech (2006) Avastin (Bevacizumab) prescribing information. Genentech, San Francisco, CA
3. Booy EP, Johar D, Maddika S, Pirzada H, Sahib MM, Gehrke I et al (2006) Monoclonal and bispecific antibodies as novel therapeutics. Arch Immunol Ther Exp (Warsz) 54(2):85-101
4. Calvo E, Rowinsky EK (2005) Clinical experience with monoclonal antibodies to epidermal growth factor receptor. Curr Oncol Rep 7(2):96-103
5. Elting LS, Fortner BV, Bosserman L, Houts AC, Schwartzberg L (2006) If at first you don't succeed, don't quit, try again: The Centers For Medicare and Medicaid Services demonstration project on quality of care-2005 and 2006. J Support Oncol 4(3):147-151
6. ImClone Systems (2006) Erbitux (Cetuximab) prescribing information. ImClone Systems and Bristol-Myers Squibb, USA
7. Fortner BV, Zhu L, Okon T (2005) The new language of cancer care: contribution to working capital, human resource costs, practice efficiency, and opportunity costs. Commun Oncol 2(4):357-362
8. Herzlinger RE (2002) Cancer care in America: description and implications of outpatient community-based cancer care. Boston Healthcare Associates, Boston
9. National Cancer Institute (2003) Common terminology criteria for Adverse Events v3.0 (CTCAE)Washington, DC
10. Biogen Idec (2007) Rituxan (Rituximab) prescribing information. Biogen Idec and Genentech, USA
11. Snyder LC, Astsaturov I, Weiner LM (2005) Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer 5(Suppl 2):S71-S80